Management tracks: Galderma taps new leadership from Shire; plus iOmx, BioSpecifics, Poseida, Kedalion, GenSight, Lyra, Verrica and Mizuho

Former Shire CEO Flemming Ørnskov will lead newly independent Galderma Laboratories L.P. as CEO. Joining him is fellow Shire vet Thomas Dittrich, who will be CFO, the same post he held at Shire. The pair led Shire through its $62 billion acquisition by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) (see “Takeda Hits the Gas”).

Ørnskov succeeds Stuart Raetzman, who joins the dermatology company’s board. The former Nestlé Skin Health unit became an independent company last week as part of a $10 billion spinout from Nestlé S.A. (SWX:NESN).

Cancer company iOmx Therapeutics AG promoted Apollon Papadimitriou to CEO from chief development officer and hired Marcus Irsfeld as CFO. Irsfeld has been CFO of multiple life sciences companies, including Averitas Pharma Inc. Steven St. Peter, managing director of Vie Ventures and former president and CEO of animal health company Aratana Therapeutics Inc. (NASDAQ:PETX), was appointed chairman, while Sofinnova Partners’ Henrijette Richter becomes vice chairman.

BioSpecifics Technologies Corp. (NASDAQ:BSTC), which is focused on collagenase-based therapies, hired Kevin Buchi as CEO. Buchi was president and CEO of TetraLogic Pharmaceuticals Corp.

Gene therapy company Poseida Therapeutics Inc. hired Kerry Ingalls as COO. He was VP of site operations at Thousand Oaks, Calif., headquarters of Amgen Inc. (NASDAQ:AMGN).

Kedalion Therapeutics Inc. said Peter Noymer has stepped down as CEO to pursue another opportunity. Co-founder and Chairman Mark Blumenkranz will take on the CEO role. The opthalmology company also promoted Casey Dougan to chief commercial officer and VP of operations from VP of corporate development, and Reynaldo Quinata to SVP of R&D from VP of engineering.

Retinal neurodegenerative diseases company GenSight Biologics S.A. (Euronext:SIGHT) promoted Magali Taiel to CMO from VP, clinical development. She succeeds Barrett Katz, who resigned to pursue another opportunity.

Ear, nose and throat disease company Lyra Therapeutics Inc. hired Dana Washburn as CMO. He was corporate VP and head of global medical services for Parexel International Corp.

Dermatology company Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) hired Eugene Scavola as EVP, technical operations. He was a managing partner at PBM Capital Group.

Mizuho Americas hired Vamil Divan as senior healthcare analyst covering large cap pharmaceutical and biotechnology companies. He was a senior analyst at Credit Suisse.

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE